Farallon Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Farallon Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,100,806	Closed	-$118M	–	190
2023 Q1	$118M	Buy	1,100,806 +955,706	+659%	+$110M	0.65%	46
2022 Q4	$16M	Buy	+145,100	New	+$9.41M	0.09%	88

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Farallon Capital Management's RXDX Position: Q2 2023 in Review

Farallon Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 1,100,806 shares — an estimated $118M sold.

Farallon Capital Management first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $118M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Farallon Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Farallon Capital Management sold 1,100,806 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $118M.
Farallon Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Farallon Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $118M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Farallon Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.